Business context and reporting period
ChromaDex Corporation (Nasdaq: CDXC), a bioscience company focused on healthy aging, filed this unaudited Form 10-Q for the three months ended March 31, 2023. Its business includes Tru Niagen consumer products, Niagen ingredient sales, and analytical reference standards and services. The filing describes the company as ChromaDex; “Niagen Bioscience” is not the registrant name shown in the filing.
Financial performance and position
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Net sales | $22.6 million | $17.3 million; up 31% |
| Gross profit / margin | $13.5 million / 59.9% | $10.5 million / 61.0% |
| Operating expenses | $15.5 million | $18.3 million |
| Operating loss | $2.0 million | $7.7 million |
| Net loss / diluted loss per share | $1.9 million / $0.03 | $7.7 million / $0.11 |
| Operating cash flow | Positive $2.8 million | Negative $7.2 million |
Revenue growth was led by Consumer Products, up 18% to $17.6 million, and Ingredients, up 189% to $4.1 million. Analytical Reference Standards and Services revenue declined 11% to $0.8 million. Niagen-related sales totaled $21.5 million. Gross margin declined about 1.1 percentage points, with consumer-product mix and inflationary costs partly offset by better ingredient-segment scale.
General and administrative expense fell 28% to $6.4 million, primarily due to lower legal costs ($1.5 million), share-based compensation ($0.7 million), and severance and restructuring expense ($0.6 million), partly offset by a $0.3 million higher doubtful-receivables provision. Cash from operations improved mainly with the lower net loss and a $2.8 million inventory cash inflow, versus a $1.7 million outflow in Q1 2022.
At March 31, cash and cash equivalents were $23.1 million, including $23.0 million unrestricted and $0.2 million restricted. Current assets were $46.6 million and current liabilities $18.4 million. There were no borrowings under the Western Alliance Bank line of credit; $7.2 million was available subject to conditions. The filing reports $15.5 million of inventory purchase commitments and $4.7 million of future operating lease payments. Total liabilities were $25.8 million, including lease obligations; no material conventional debt balance was reported.
Material changes, outlook and risks
- Management attributed Tru Niagen growth to e-commerce and higher sales to related-party customer A.S. Watson. E-commerce was expected to remain the primary growth catalyst for 2023; the filing provides no quantified revenue or earnings guidance.
- Management said unrestricted cash and expected cash generation from sales should cover obligations for at least the next 12 months, while noting it may seek capital for later operating plans or strategic objectives. The filing identifies recurring losses, historical negative operating cash flow and inflation as liquidity concerns; it also says the ATM facility’s availability is materially limited by its conditions and market factors.
- Five customers represented approximately 86% of trade receivables at quarter-end. A.S. Watson, a related party, accounted for 16.5% of quarterly sales and 38.0% of receivables. Management cited purchase timing and monitoring practices but acknowledged the risk of delayed or defaulted payments.
- Key risks include continued losses, dependence on Tru Niagen, customer and supplier concentration (W.R. Grace is the exclusive NR manufacturer), inflation and macroeconomic pressures, regulatory and product-claim scrutiny, and patent and other litigation. The filing notes prior FDA/FTC warning letters concerning COVID-related statements; management did not expect the matter to be material.
- In litigation, the Federal Circuit affirmed invalidation of the Dartmouth-licensed patent claims in the Elysium patent case on February 13, 2023. A rehearing petition was denied May 10, 2023, after quarter-end; management said the decision was not expected to materially affect the NR business. Separate Elysium matters remained subject to appeal or stay, and the company said it could not reasonably estimate a possible loss for the SDNY matter.
- The company adopted the expected-credit-loss standard, recording a $29,000 reduction to opening retained earnings. It received $0.8 million of employee retention tax credit proceeds in Q1 and reported a $1.0 million remaining benefit, with $0.2 million of associated commissions payable, at quarter-end.
- Management concluded disclosure controls were effective at the reasonable-assurance level and reported no material first-quarter change in internal control over financial reporting.
Important facts for investors to verify
- Whether revenue growth—particularly in Niagen ingredient sales and e-commerce—continues, and how customer mix affects gross margin.
- Whether operating cash flow remains positive after the Q1 inventory reduction, and how inventory purchase commitments affect liquidity.
- Customer receivables concentration, collection performance, and A.S. Watson’s related-party sales and balances.
- Liquidity assumptions, credit-line conditions, and the potential need for new financing or dilution.
- Developments in Elysium litigation, patent challenges, regulatory matters, and China’s required Blue Hat registration for the joint venture.